Home Drug Guide Talquetamab-tgvs

Drug Guide

Generic Name

Talquetamab-tgvs

Brand Names Talvey

Classification

Therapeutic: Antineoplastic; Monoclonal Antibody

Pharmacological: G protein-coupled receptor class antibody targeting GPRC5D

FDA Approved Indications

Relapsed or refractory multiple myeloma in adult patients

Mechanism of Action

Talquetamab-tgvs is a bispecific T-cell engager (BiTE) antibody that binds to GPRC5D on myeloma cells and CD3 on T-cells, redirecting T-cell mediated cytotoxicity to eliminate myeloma cells.

Dosage and Administration

Adult: Typically administered intravenously at specified intervals (e.g., weekly), dosed based on clinical trials and physician discretion.

Pediatric: Not approved for pediatric use.

Geriatric: No specific adjustments identified; use with caution, considering renal/hepatic function.

Renal Impairment: No specific dosage adjustments available; monitor closely.

Hepatic Impairment: No specific data; use with caution and monitor hepatic function.

Pharmacokinetics

Absorption: Not applicable (administered IV).

Distribution: Expected to distribute widely, including into tissues.

Metabolism: Metabolized as a protein, primarily cleared via reticuloendothelial system.

Excretion: Degraded into amino acids and peptides.

Half Life: Approximately 1-2 weeks, based on similar monoclonal antibodies.

Contraindications

Hypersensitivity to talquetamab-tgvs or its components.

Precautions

Monitor for cytokine release syndrome, neurotoxicity, infections, and infusion-related reactions.

Adverse Reactions - Common

Cytokine release syndrome (Common (≥20%))
Neurotoxicity (Uncommon)
Infections (Common)
Infusion reactions (Common)

Adverse Reactions - Serious

Severe cytokine release syndrome (Less common)
Kaposi's sarcoma or other malignancies (Long-term risk) (Rare)

Drug-Drug Interactions

Other immunosuppressants, chemotherapy agents, or drugs affecting immune function.

Drug-Food Interactions

N/A

Drug-Herb Interactions

N/A

Nursing Implications

Assessment: Monitor for signs of cytokine release syndrome, neurotoxicity, infections, infusion reactions.

Diagnoses:

Risk for infection
Impaired tissue perfusion related to cytokine release syndrome

Implementation: Administer as prescribed, monitor vital signs closely during and after infusion, prepare for management of infusion reactions.

Evaluation: Assess response to therapy, monitor adverse effects, and support patient needs.

Patient/Family Teaching

Report any fever, chills, or infusion reactions.
Be aware of signs of infection or neurological changes.
Follow schedule for infusions and appointments.
Understand the importance of adhering to therapy and reporting side effects.

Special Considerations

Black Box Warnings:

Cytokine release syndrome (CRS)
Neurologic toxicities, including ICANS

Genetic Factors: Not specifically relevant for this therapy.

Lab Test Interference: May cause transient lymphopenia and cytopenias; monitor CBC and other labs regularly.

Overdose Management

Signs/Symptoms: Severe infusion reactions, cytokine release syndrome, neurotoxicity.

Treatment: Supportive care, corticosteroids, antipyretics, and ICU support as needed; circulation and airway management.

Storage and Handling

Storage: Store in a refrigerator at 2°C to 8°C (36°F to 46°F).

Stability: Stable under refrigeration; protect from light.